Biologics Market Trends: Monoclonal Antibodies, Biosimilars Growth & Forecast to 2034

Biologics have fundamentally changed what is possible in medicine. Where conventional small-molecule drugs treat symptoms broadly, biologics — derived from living organisms and including monoclonal antibodies, gene therapies, recombinant proteins, and vaccines — target the specific molecular mechanisms driving disease. The results are visible in oncology wards, rheumatology clinics, and diabetes management programmes worldwide: better outcomes, fewer side effects, and treatment options for conditions that previously had none. The scale of commercial investment now reflects that clinical reality. According to IMARC Group, the global biologics market size was valued at USD 377.6 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 769.7 Billion by 2033, exhibiting a CAGR of 7.38% during 2025–2033. North America currently dominates the market, holding a market share of over 44.8% in 2024.

The market spans a richly segmented product and disease landscape. Monoclonal antibodies dominate by product with a 66.7% share — their precision in targeting specific antigens has made them indispensable across oncology, autoimmune disorders, and infectious diseases. Microbial sources lead manufacturing at 58.5%, driven by the cost-efficiency and scalability of E. coli and yeast-based production systems. Oncology holds the largest disease segment at 28.7%, backed by rising global cancer incidence and the rapid expansion of checkpoint inhibitors and CAR-T therapies. In-house manufacturing commands an 84.8% share, as leading biopharmaceutical companies prioritise direct quality control and intellectual property protection over contract production.

Get a Sample Report for Actionable Market Insights

Biologics Market Growth Drivers:

• Chronic Disease Burden Creating Structural, Long-Term Demand for Advanced Biologics

The epidemiological case for biologics investment is straightforward and growing. WHO projects that chronic diseases account for approximately 74% of all deaths globally, with cancer, cardiovascular disease, diabetes, and autoimmune conditions representing the heaviest burden. Average private healthcare spending in the US has reached USD 11,197 per person annually, a figure that reflects both the clinical need and the financial system's capacity to pay for advanced therapies. As populations age and lifestyle-related conditions multiply, the demand for targeted biological treatments that outperform conventional pharmaceuticals in both efficacy and tolerability is structurally embedded in healthcare systems worldwide.

• Biosimilar Expansion Making Biologics Accessible to Vastly Wider Patient Populations

One of the most commercially significant developments in this market is the maturation of the biosimilar segment. As blockbuster biologics come off patent, biosimilar manufacturers are launching cost-effective alternatives that bring biologics within reach of health systems and patients previously priced out. Biocon Biologics secured US market access for its biosimilar YESINTEK covering over 100 million lives — roughly 70–80% of the commercial market — in a single formulary push. India's government healthcare spending reached approximately USD 51 billion, with public investment targeted to reach 2.5% of GDP, directly funding biosimilar accessibility programmes through initiatives like Ayushman Bharat.

• Regulatory Harmonisation Accelerating Global Market Entry for Novel Biologics

Biologics development has long been hampered by fragmented regulatory requirements across major markets — different standards in the US, EU, Japan, and emerging economies meant years of duplicated trial work before a therapy could reach a global patient base. The ICH's Good Clinical Practice E6(R3) guidance, issued in coordination with the US FDA, explicitly aims to create unified standards that facilitate mutual acceptance of clinical data across member countries. For biopharmaceutical companies, this means faster multi-market approvals, lower development costs, and quicker patient access — a combination that directly accelerates both R&D investment returns and the commercial expansion of approved biologics.

Biologics Market Trends:

• Next-Generation Targeted Therapies Pushing Oncology Treatment Outcomes Dramatically Higher

The precision oncology revolution is being written in biologics. Between 2006 and 2020, genomic-targeted therapy approvals for cancer expanded eligibility from 5.13% to 13.60% of patients, while genome-informed therapies pushed eligibility further to 27.30%. Response rates improved from 2.73% to 11.10% — numbers that represent millions of additional patients experiencing meaningful clinical benefit. CAR-T cell therapy, bispecific antibodies, and checkpoint inhibitors are all biologics-based and represent some of oncology's most significant clinical advances. Caltech researchers' ultrasound-activated drug delivery system combining gas vesicles and mechanophores to activate drugs precisely at tumour sites exemplifies where the next wave of targeted biologic therapy innovation is heading.

• Advanced Drug Delivery Innovation Transforming Patient Compliance and Therapeutic Outcomes

How a biologic is delivered matters enormously — both for its clinical effectiveness and for whether patients actually stick with treatment. The nanotechnology-based drug delivery market crossed USD 125 billion, reflecting massive investment in systems that improve the stability, targeting, and release profiles of biologic molecules. The University of North Carolina's Spatiotemporal On-Demand wireless patch — a smartphone-controlled microneedle device — points toward a future where patients manage complex biologic dosing with the simplicity of a wearable. Forge Biologics' partnership with Fractyl Health to manufacture Rejuva, an AAV-based gene therapy for obesity and type 2 diabetes, shows how delivery innovation and biologics manufacturing are converging in entirely new therapeutic categories.

• CDMO Capacity Expansion Reshaping the Biologics Manufacturing Landscape

The demand for biologics manufacturing capacity has outpaced what even the largest pharmaceutical companies can build internally, creating a thriving contract development and manufacturing organisation ecosystem. Lonza's USD 1.2 billion acquisition of Roche's California biologic drug manufacturing site — described as one of the largest facilities of its class — is the clearest signal of where the industry is investing. Samsung Biologics' adoption of a Quality-by-Design framework across its CDMO operations reflects growing recognition that manufacturing quality is a competitive differentiator, not just a compliance requirement. WuXi Biologics' commercial manufacturing partnership for VG712, an anti-CD3 immunotoxin targeting cancer and autoimmune diseases, further illustrates how CDMOs are becoming central to biologic pipeline progression globally.

Recent News and Developments in the Biologics Market

• June 2025: WuXi Biologics announced a commercial manufacturing partnership with Virogen Biotechnology to support production of VG712, a first-in-class anti-CD3 immunotoxin targeting immune system reset for cancer and autoimmune diseases. WuXi will provide technology transfer, process validation, and full-scale manufacturing, enabling VG712's progression toward a planned Biologics License Application.

• May 2025: Forge Biologics announced a manufacturing partnership with Fractyl Health to support development of Rejuva, an AAV-based pancreatic gene therapy targeting obesity and type 2 diabetes. Forge will provide process development, cGMP manufacturing, and analytical services using its FUEL platform at its 200,000 square foot facility in Columbus, Ohio.

• May 2025: Biocon Biologics announced market access for YESINTEK (ustekinumab-kfce) across major US formularies, reaching coverage for over 100 million lives — approximately 70–80% of the commercial market. The biosimilar to Stelara was approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis following US FDA approval in December 2024.

• April 2025: Samsung Biologics highlighted its adoption of a Quality-by-Design framework to enhance biopharmaceutical product lifecycle management, spanning from process characterisation to commercial manufacturing. The strategy aims to improve consistency, compliance, and scalability across its contract development and manufacturing operations.

• March 2024: Lonza acquired Roche's California biologic drug manufacturing site for USD 1.2 billion. The facility, one of the largest biologic manufacturing sites of its class, strengthens Lonza's global biologics production capacity and fits directly into its growth strategy as demand for biologic drugs continues to expand across all major therapeutic areas.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.